Medigene AG (ETR:MDG1 – Get Free Report)’s share price rose 1.4% during mid-day trading on Tuesday . The stock traded as high as €1.10 ($1.13) and last traded at €1.02 ($1.05). Approximately 27,090 shares were traded during trading, a decline of 91% from the average daily volume of 306,207 shares. The stock had previously closed at €1.01 ($1.04).
Medigene Trading Down 2.9 %
The business’s fifty day moving average price is €1.32 and its 200 day moving average price is €1.45. The firm has a market capitalization of $15.06 million, a PE ratio of -0.84, a P/E/G ratio of 7.12 and a beta of 0.84. The company has a quick ratio of 5.85, a current ratio of 2.39 and a debt-to-equity ratio of 12.94.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Recommended Stories
- Five stocks we like better than Medigene
- What does consumer price index measure?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Best Stocks Under $5.00
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What is the Australian Securities Exchange (ASX)
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
